MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.040
+0.119
+6.19%
Closed 16:00 05/24 EDT
OPEN
1.900
PREV CLOSE
1.921
HIGH
2.040
LOW
1.878
VOLUME
3.58K
TURNOVER
4.98K
52 WEEK HIGH
6.40
52 WEEK LOW
1.510
MARKET CAP
46.09M
P/E (TTM)
-1.0557
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 5d ago
CIG, BTCM and CYAD among mid-day movers
Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%.
Seekingalpha · 5d ago
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapie...
GlobeNewswire · 05/17 20:05
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for ca...
GlobeNewswire · 05/05 22:12
Celyad Oncology reports Q1 results
Celyad Oncology press release (NASDAQ:CYAD): Q1 Net cash burn amounted to €9.5M ($10.6 million), in line with expectations. Cash and cash equivalents of €20.5M. The company confirms its previous guidance
Seekingalpha · 05/05 21:41
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
Highlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patientsInvestigation ongoing of findings in CYA...
GlobeNewswire · 03/24 20:05
Celyad Oncology GAAP EPS of -€1.70
Celyad Oncology press release (NASDAQ:CYAD): FY GAAP EPS of -€1.70. Cash position of €30.0 million ($34.0 million) as of December 31, 2021
Seekingalpha · 03/24 20:04
Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
MONT-SAINT-GUIBERT, Belgium, March 17, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen recep...
Business Wire · 03/17 06:01
More
No Data
Learn about the latest financial forecast of CYAD. Analyze the recent business situations of Celyad Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
25.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYAD stock price target is 10.55 with a high estimate of 13.06 and a low estimate of 8.04.
High13.06
Average10.55
Low8.04
Current 2.040
EPS
Actual
Estimate
-1.07-0.80-0.54-0.27
2020/06
2020/12
2021/06
2021/12
2022/06
Institutional Holdings
Institutions: 15
Institutional Holdings: 6.62M
% Owned: 29.30%
Shares Outstanding: 22.59M
TypeInstitutionsShares
Increased
1
10.85K
New
6
6.57M
Decreased
3
2.05K
Sold Out
3
148.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Michel Lussier
Chief Executive Officer/Chief Financial Officer/Executive Board/Director
Filippo Petti
Chief Human Resource Officer/Executive Board
Philippe Nobels
Chief Scientific Officer/Executive Board
David Gilham
Vice President/Executive Board
Fredrik Lehmann
Other
Charles Morris
Executive Board/Secretary
Philippe Dechamps
Executive Board
Stephen Rubino
Non-Executive Director
Chris Buyse
Non-Executive Director
Rudy Dekeyser
Non-Executive Director
Serge Goblet
Independent Director
Maria Koehler
Independent Director
Dominic Piscitelli
Independent Director
Marina Udier-Blagovic
Independent Director
Hilde Windels
No Data
No Data
About CYAD
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Webull offers kinds of Celyad Oncology SA stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.